Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$1.18
+2.2%
$1.27
$0.85
$4.40
$37.97M0.2131,312 shs2,252 shs
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.02
-0.7%
$5.64
$2.81
$485.37
$2.30M5.58607,584 shs130,195 shs
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$0.40
-0.5%
$4.04
$3.36
$26.30
$3.76M1.51628,703 shs68,057 shs
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
$8.00
$0.80
$4.80
$122.94M1.07177,606 shsN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$2.03
-0.7%
$2.28
$1.90
$4.21
$58.31M0.61177,661 shs107,238 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00%+1.80%-12.59%+8.26%-62.91%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.00%-1.95%-39.11%-89.87%-99.96%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-0.54%-7.40%-10.69%-7.83%-58.90%
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%+2.79%-15.27%-13.83%-38.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
1.5428 of 5 stars
0.05.00.00.01.83.30.0
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
2.132 of 5 stars
3.53.00.00.00.60.01.3
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.387 of 5 stars
0.05.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.007,252,880.13% Upside
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00
N/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
0.00
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest APVO, AKTX, AZRX, SBPH, and VTGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A$0.84 per shareN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.74N/AN/A$65.21 per share0.05
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A($0.76) per shareN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/AN/AN/AN/A$2.16 per shareN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$490K120.51N/AN/A$2.44 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$19.79MN/A0.00N/AN/A-213.59%-65.60%8/18/2025 (Estimated)
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)

Latest APVO, AKTX, AZRX, SBPH, and VTGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/A
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/A
0.16
0.16
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
0.67
0.67
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/A
1.33
1.33
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
N/A
5.11
5.11
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
6.51
6.51
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
932.18 million19.92 millionNot Optionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50760,000756,000Not Optionable
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
129.33 million8.65 millionNot Optionable
Spring Bank Pharmaceuticals, Inc. stock logo
SBPH
Spring Bank Pharmaceuticals
3017.27 millionN/ANot Optionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4029.16 million28.78 millionOptionable

Recent News About These Companies

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.18 +0.03 (+2.16%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$3.02 -0.02 (-0.66%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$3.02 +0.00 (+0.03%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

AzurRx BioPharma stock logo

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Spring Bank Pharmaceuticals stock logo

Spring Bank Pharmaceuticals NASDAQ:SBPH

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$2.02 -0.02 (-0.74%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$2.03 +0.00 (+0.25%)
As of 07/3/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.